U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07653503) titled 'Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)' on June 11.
Brief Summary: We aim to determine feasibility, safety and efficacy of TDLN-targeted immune checkpoint inhibition in different doses (nivolumab) in patients with cervical cancer.
Study Start Date: Jan. 05
Study Type: INTERVENTIONAL
Condition:
Cervical Carcinoma
Intervention:
DRUG: Nivolumab
Subcutaneous injection of nivolumab
Recruitment Status: RECRUITING
Sponsor: University Medical Center Groningen
Published by HT Digital Content Services with permission from Health Daily Digest....